NCT05198596View on ClinicalTrials.gov

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above

PHASE3CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

July 30, 2022

Primary Completion Date

November 4, 2022

Study Completion Date

March 30, 2023

Conditions
COVID-19 Vaccine
Interventions
BIOLOGICAL

MVC-COV1901

Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

BIOLOGICAL

AZD1222

Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Trial Locations (2)

34000

Sunpasitthiprasong Hospital, Ubon Ratchathani

34190

College of Medicine and Public Health, Ubon Ratchathani University, Warin Chamrap

Sponsors
All Listed Sponsors
lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT05198596 - A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above | Biotech Hunter | Biotech Hunter